Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with proteinuria

Kidney and Blood Pressure Research

Volumn 39, Issue 6, 2014, Pages 573-580

  Kim, Ha Yeon ^a   Bae, Eun Hui ^a   Ma, Seong Kwon ^a   Kim, Soo Wan ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Aldosterone escape; Proteinuria; Spironolactone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POLYSTYRENESULFONATE SODIUM; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADD ON THERAPY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; TREATMENT DURATION; URINE ALBUMIN TO CREATININE RATIO; UROGENITAL SYSTEM PARAMETERS; AGED; DRUG COMBINATION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROTEINURIA; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 84919958930     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368470     Document Type: Article

References (23)

1. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis 2008;51:199-211
2. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
3. Lee AF, MacFadyen RJ, Struthers AD: Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: A longitudinal study. Eur J Heart Fail 1999;1:401-406
4. Mandal AK: Hypokalemia and hyperkalemia. Med Clin North Am 1997;81:611-639
5. Granger JP, Kassab S, Novak J, Reckelhoff JF, Tucker B, Miller MT: Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol 1999;276:R197-202
6. Lakkis J, Lu WX, Weir MR: RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003;5:408-417
7. Bianchi S, Bigazzi R, Campese VM: Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 2005;46:45-51
8. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M: Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 2010;332:1072-1080
9. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T: Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006;47:1084-1093
10. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-Aldosterone hypertensive rats. Hypertension 2006;47:656-664
11. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T: Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension 2007;49:355-364
12. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M: Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 2011;26:2475-2484
13. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
14. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553
15. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P: Design of combination angiotensin receptor blocker and angiotensinconverting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009;4:361-368
16. Shavit L, Lifschitz MD, Epstein M: Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: Current concepts and emerging treatment paradigms. Kidney Int 2012;81:955-968
17. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, crossover study. Diabetes Care 2005;28:2106-2112
18. Khosla N, Kalaitzidis R, Bakris GL: Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009;30:418-424
19. Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M: Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: A randomized clinical trial. Nephrol Dial Transplant 2013;28:2823-2833
20. Morales E, Millet VG, Rojas-Rivera J, Huerta A, Gutierrez E, Gutierrez-Solis E, Egido J, Praga M: Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 2013;28:405-412
21. Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006;70:2116-2123
22. Bunda S, Wang Y, Mitts TF, Liu P, Arab S, Arabkhari M, Hinek A: Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2009;284:16633-16647
23. Ren Y, D'Ambrosio MA, Liu R, Pagano PJ, Garvin JL, Carretero OA: Enhanced myogenic response in the afferent arteriole of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010;298:H1769-1775